CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients

Recent years have witnessed the groundbreaking success of immune checkpoint blockage (ICB) in metastasized malignant melanoma. However, biomarkers predicting the response to ICB are still urgently needed. In the present study, we investigated CTLA4 promoter methylation (mCTLA4) in 470 malignant mela...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCI Insight
Hlavní autoři: Goltz, Diane, Gevensleben, Heidrun, Vogt, Timo J., Dietrich, Joern, Golletz, Carsten, Bootz, Friedrich, Kristiansen, Glen, Landsberg, Jennifer, Dietrich, Dimo
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6124533/
https://ncbi.nlm.nih.gov/pubmed/29997292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96793
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky